Study Summary
This trial is testing the safety of a new meningitis B vaccine in adults, adolescents, toddlers, and infants. The vaccine will be given either alone or with other routine vaccines. The study will also look at the vaccine's ability to generate an immune response.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
8 Primary · 4 Secondary · Reporting Duration: Day 01, Day 31, Day 61, Day 91, Day 181, Day 211, Day 366 and Day 396
Trial Safety
Safety Progress
Trial Design
8 Treatment Groups
Stage 1: vaccine comparator(s)
1 of 8
Stage 2: vaccine comparator(s)
1 of 8
Stage 4: MenQuadfi vaccine and vaccine comparator
1 of 8
Stage 3: MenQuadfi vaccine and vaccine comparator
1 of 8
Stage 1: MenB vaccine formulation(s)
1 of 8
Stage 4: MenB vaccine formulation(s)
1 of 8
Stage 2: MenB vaccine formulation(s)
1 of 8
Stage 3: Men B vaccine formulation(s)
1 of 8
Active Control
Experimental Treatment
1800 Total Participants · 8 Treatment Groups
Primary Treatment: Meningococcal Group B Vaccine MenB · Has Placebo Group · Phase 1 & 2
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age < 65 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 26th, 2021
Last Reviewed: November 26th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.